This special series on Impact of Novel Neoadjuvant Treatment on Surgery Outcomes in Lung Cancer is co-edited by Dr. Dragana Jovanovic, from Internal Medicine Clinic “Akta Medica”, Belgrade, Serbia; and Dr. Semra Bilaceroglu, from Izmir Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey.
Preface on neoadjuvant treatment in lung cancer—some facts on the outcomes
Imaging procedures in the assessment of response to neoadjuvant treatment in non-small cell lung cancer
The role of immunotherapy in neoadjuvant treatment of non-small cell lung cancer—a narrative review
Biomarkers under investigation for neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer
Challenges of neoadjuvant targeted therapy in early stage non-small cell lung cancer—a narrative review
The role of endosonography-guided fine needle aspiration in preoperative restaging in the era of novel neoadjuvant therapies—a literature review
Thoracic surgical challenges after neoadjuvant immunotherapy for non-small cell lung cancer: a narrative review
Pathological response characteristics and surgical outcome following use of emerging neoadjuvant treatment strategies in lung cancer: a narrative review
Disclosure:
The series “Impact of Novel Neoadjuvant Treatment on Surgery Outcomes in Lung Cancer” was commissioned by the editorial office, AME Surgical Journal without any sponsorship or funding. Dragana Jovanovic and Semra Bilaceroglu served as the unpaid Guest Editors for the series.